Skip to main content
padlock icon - secure page this page is secure

The Medicinal Potential of Natural Products for the Development of Anti- Influenza Agents

Buy Article:

$68.00 + tax (Refund Policy)

Influenza neuraminidase (NA) is an important target for designing anti-influenza drugs. By now, three inhibitors, zanamivir, oseltamivir and peramivir have been approved. However, in recent years, the potential threat of influenza pandemics and constant emergence of new drug-resistant influenza virus strains have weaken the defensive role of the current anti-influenza drugs. From another point of view, in this review we focused on some novel NA inhibitors which were mainly derived from natural products that had a variety of structural scaffolds, such as flavonoids, xanthones and diarylheptanoids. Besides interfering the function of NA, some of these compounds also can potently inhibit the replication of influenza virus. It is hoped that these compounds could be the source of leads and provide a guide for discovering new potent anti-influenza virus agents.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Diarylheptanoids; flavonoids; influenza virus; inhibitor; neuraminidase; xanthones

Document Type: Research Article

Publication date: February 1, 2014

More about this publication?
  • Current Drug Targets aims to cover the latest and most outstanding developments on the medicinal chemistry and pharmacology of molecular drug targets e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will be devoted to a single timely topic, with series of in-depth reviews, written by leaders in the field, covering a range of current topics on drug targets. These issues will be organized and led by a guest editor who is a recognized expert in the overall topic. As the discovery, identification, characterisation and validation of novel human drug targets for drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more